Network-pharmacology-based research on protective effects and underlying mechanism of Shuxin decoction against myocardial ischemia/reperfusion injury with diabetes

Figure 12  Shuxin decoction reduces oxidized low density lipoprotein and activates advanced glycation end products-receptor for advanced glycation end products signaling pathway. A: Oxidized low density lipoprotein levels at the end of the experiment; B: Blood advanced glycation end products (AGEs) at the end of the experiment; C: Percentage of positive receptor for AGE (RAGE) (red/blue fluorescence, magnification × 20, scale bars, 50 μM); D: Immunofluorescence of RAGE. The RAGE-positive cells are stained red, while nuclei of cardiomyocytes are blue; E: RAGE protein levels detected by Western blot; F: Statistics of gray value of RAGE/GAPDH based on Western blot. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs group C. ^dP < 0.05, ^eP < 0.01, ^fP < 0.001 vs myocardial ischemia/reperfusion injury in diabetes group (n = 3 rats per group). C: Normal control group; DS: Diabetic rats with sham operation group; MI/RI: Myocardial ischemia/reperfusion injury; DMR: MI/RI in diabetes group; SXTL: MI/RI in diabetic rats receiving SXT 0.7 g/kg/d group; SXTM: MI/RI in diabetic rats receiving SXT 1.4 g/kg/d group; SXTH: MI/RI in diabetic rats receiving SXT 2.8 g/kg/d group; ox-LDL: Oxidized low density lipoprotein.